The current state of preclinical prostate cancer animal models

Prostate

Volumn 68, Issue 6, 2008, Pages 629-639

  Pienta, Kenneth J ^a,q   Abate Shen, Cory ^b   Agus, David B ^c   Attar, Ricardo M ^d   Chung, Leland W K ^e   Greenberg, Norman M ^f   Hahn, William C ^g   Isaacs, John T ^h   Navone, Nora M ⁱ   Peehl, Donna M ^j   Simons, Jonathon W ^k   Solit, David B ^l   Soule, Howard R ^k   VanDyke, Terry A ^m   Weber, Michael J ⁿ   Wu, Lily ^o   Vessella, Robert L ^p  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g HARVARD UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j STANFORD UNIVERSITY   (United States)

^k Prostate Cancer Foundation   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF VIRGINIA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^q NONE   (United States)

more..

Author keywords

Cell lines; Genetically engineered; Mouse

Indexed keywords

ANIMAL MODEL; BIODIVERSITY; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CELL LINE; EPIGENETICS; GENETIC ENGINEERING; GENETIC VARIABILITY; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNIVERSITY HOSPITAL; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS;

EID: 42949126281     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20726     Document Type: Review

References (43)

1. Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117(9):2351-2361.
2. Majumder PK, Sellers WR. Aktregulated pathways in prostate cancer. Oncogene 2005;24:7465-7474.
3. Jong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-447.
4. Cansino Alcaide JR, Martinez-Pineiro L. Molecular biology in prostate cancer. Clin Transi Oncol 2006;8:148-152.
5. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005;14:949-957.
6. Mazzucchelli R, Barbisan F, Tarquini LM, Galosi AB, Stramazzotti D. Molecular mechanisms in prostate cancer. A review. Anal Quant Cytol Histol 2004;26:127-133.
7. Prowatke I, Devens F, Brenner A, Gröne EG, Mertens D, Gröne HJ, Lichter P, Joos S. Expression analysis of unbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer 2007; 96:82-88.
8. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2005;5:1886-1901.
9. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12:1665-1671.
10. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-1490.
11. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8:411-419.
12. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
13. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Keufer R, Lee C, Montie JM, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
14. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jerónimo C, Teixeira MR. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832.
15. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101.
16. Rinker-Schaeffer CW, Wharam JF, Simons J, Isaacs JT. Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase. Prostate 1996;29:60-64.
17. Isaacs JT. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 1989;49:6290-6294.
18. Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 1988;13:263-272.
19. Isaacs JT. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res 1982;42(12):5010-5014.
20. Isaacs JT, Heston WD, Weissman RM, Coffey DS. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 1978;38:4353-4359.
21. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006;66:1213-1222.
22. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines- part 1. J Urol 2005;173:342-359.
23. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-part 2. J Urol 2005;173:360-372.
24. Sobel RE, Wang Y, Sadar MD. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In Vitro Cell Dev Biol Anim 2006;42:33-39.
25. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
26. van Bokhoven A, Caires A, Maria MD, Schulte AP, Lucia MS, Nordeen SK, Miller GJ, Varella-Garcia M. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 2003;57:226-244.
27. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3. 0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-180.
28. Simin K, Hill R, Song Y, Zhang Q, Bash R, Cardiff RD, Yin C, Xiao A, McCarthy K, van Dyke T. Deciphering cancer complexities in genetically engineered mice. Cold Spring Harb Symp Quant Biol 2005;70:283-290.
29. Abdulkadir SA, Kim J. Genetically engineered murine models of prostate cancer: Insights into mechanisms of tumorigenesis and potential utility. Future Oncol 2005;1:351-360.
30. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-2305.
31. Kasper S. Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 2005; 94:279-297.
32. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237.
33. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2(2):70-75.
34. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
35. Shen MM, Abate-Shen C. Pten inacti vation and the emergence of androgen-independent prostate cancer. Cancer Res 2007;67: 6535-6538.
36. Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006;12: 5305-5311.
37. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, Zhou Z, Nikitin AY, Roy-Burman P. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525-7533.
38. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-221.
39. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436: 725-730.
40. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 2007;67:9089-9096.
41. Gao H, Ouyang X, Banach-Petrosky WA, Shen MM, Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 2006;66:7929-7933.
42. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 2006;103:14477-14482.
43. Mogal AP, van der Meer R, Crooke PS, Abdulkadir SA. Haploinsufficient prostate tumor suppression by Nkx3.1: A role for chromatin accessibility in dosage-sensitive gene regulation. J Biol Chem 2007;282:25790-25800.